

Approval of pembrolizumab (MSI-H/dMMR) and considerations for site-agnostic development of drugs in oncology

Steven Lemery, MD, MHS Associate Director, DOP2




Traditional development paradigm

- Based on tumor type, e.g.,
 - Previously untreated pancreatic cancer
 - HCC after previous sorafenib treatment
- Based on a biomarker within a tumor type, e.g.,
 - HER-2 positive breast or gastric cancer
 - RAS wild-type colorectal cancer



MSI-H/dMMR, not the organ, defines the indication





What is MSI-H/dMMR?

- MSI-H = microsatellite instability
- dMMR = deficient mismatch repair
- Causes of dMMR/MSI-H:
 - Mutation in DNA repair proteins
 - Can occur in Lynch syndrome
 - Inactivation of DNA repair proteins




Why does this matter?

- Impairment in mismatch repair causes
 - $-\uparrow\uparrow\uparrow$ mutations in tumors
 - Some mutations (neo-antigens) may be targeted by immune system
- Pembrolizumab can facilitate immune system response in some MSI-H/dMMR cancers



MSI-H in different tumor types



Bonneville et al., JCO Precision Oncology, 2017



Initial Interaction with Merck

• FDA discussed KN-16 with Merck in May 2015

– ORR:

- 4/10 MSI-H CRC
- 5/7 MSI-H other tumors
- 0/18 MSS CRC
- Discussed design of KN-164 (MSI-H CRC)
 - FDA recommended enrolment of patients with other MSI-H GI cancers
 - FDA recommended that Merck submit a BTDR.




Pre-BLA regulatory history

Date	Event		
Jul 2015	FDA and Merck met to discuss development in MSI-H non-CRC		
Oct 2015	BTDR granted for MSI-H CRC		
Mar 2016	Enrollment in KN-164 complete; new cohort to be opened		
Apr 2016	Merck provided FDA an update of development program		
Jul 2016	Pre-BLA meeting: FDA informed Merck that Agency amenable to TA indication		
Oct 2016	BTDR granted for MSI-H non CRC		



Data supporting pembrolizumab approval

		Objective response rate	
	Ν	n (%)	95% CI
CRC	90	32 (36%)	(26%, 46%)
Non-CRC	59	27 (46%)	(33%, 59%)
Endometrial cancer	14	5 (36%)	(13%, 65%)
Biliary cancer	11	3 (27%)	(6%, 61%)
Gastric or GE junction cancer	9	5 (56%)	(21%, 86%)
Pancreatic cancer	6	5 (83%)	(36%, 100%)
Small intestinal cancer	8	3 (38%)	(9%, 76%)
Breast cancer	2	PR, PR	
Prostate cancer	2	PR, SD	
Bladder cancer	1	NE	
Esophageal cancer	1	PR	
Sarcoma	1	PD	
Thyroid cancer	1	NE	
Retroperitoneal adenocarcinoma	1	PR	
Small cell lung cancer	1	CR	
Renal cell cancer	1	PD	



KM-DOR in 59 responding patients

Source: Keytruda labeling, BLA submission, FDA review documents



Pembrolizumab MSI-H approval considerations

- Strong scientific/biological rationale
- Compelling clinical data
- Extensive history of clinical use / safety profile
- Favorable risk/benefit profile with similar ORR in other indications
- Approved for patients without available therapies



Pembrolizumab MSI-H/dMMR approval

- Granted accelerated approval
 - ORR/DOR data post-approval
 - Over 400 patients with at least 25 tumors enrolled
- AA requirement: advantage over available therapy
 - CRC: prior FP, oxaliplatin, irinotecan
 - Other solid tumors: progressed on available therapies and no satisfactory options
 - This requirement does not apply to regular approval
- Companion IVD PMCs

TA approval/development considerations

- 1. How many tumor types should be evaluated?
- 2. Extrapolation to non-studied tumor types/pediatrics?
- 3. Accelerated versus regular approval?
- 4. How will residual uncertainty be managed?
 - e.g., if a drug is ineffective for a particular rare-tumor biomarker
 - Pre-approval
 - Post-approval (e.g., trials, registries, RWD)



How many tumor types should be evaluated?

- No "one size fits all" answer
 - Does the totality of evidence support approval?
 - Were common tumor types studied?
 - Was effect generally consistent among tumors?
 - Is approach scientifically supportable?



Extrapolation* – Yes, if appropriate

- Pembrolizumab:
 - At time of approval, responses observed in *at least* 14 MSI-H/dMMR tumor types
 - No pattern indicating a qualitative effect of tumor type on response



Pediatrics: Pembrolizumab – MSI-H

- Dose of pembrolizumab established in children
- Pembrolizumab approved in children with cHD
- Biology of MSI-H (e.g., increased mutation burden) expected to be similar in children



TA – General Pediatric Considerations

- Consider formulations *early* during development
- Initiate pediatric trials early
 - Establish dose in all age groups
 - Consider enrolling patients age 12 years or older in adult trials



Approval Considerations

- RCTs to assess OS in rare biomarker(+) tumor types with unprecedented effects on ORR and DOR
 - May not be feasible
 - Probably not ethical in refractory setting
- For pembrolizumab, OS/PFS improvements in other cancers with similar ORR and high TMB (e.g., melanoma, NSCLC)
- FDA took similar approach with crizotinib for ROS1postive NSCLC



Uncertainty

- Absolute certainty regarding drug effect will not exist for every biomarker-tumor-drug combination
 - Sponsors need to make the case that the approach is appropriate based on scientific/clinical data
- Absolute certainty *also* does not exist in tumorspecific approvals



How to address uncertainty

- Pre-market: Is data package sufficient (FDA approval decision)
 - Substantial evidence standard
- Post-market trials (e.g., for pembrolizumab)
- Real world-data?



Pre-market data requirements

- Sufficient data to make a risk-benefit determination
- Sufficient data that the effect is "real"
- Influenced by
 - magnitude of benefit
 - known toxicity profile
 - unmet need / lack of available therapies
 - risk to patient of no treatment



The future for MSI-H?

- Earlier treatment?
 - First-line metastatic CRC?
 - Adjuvant use
 - ? Role for first-line in other tumor-types
- Identify patients less likely to respond
- How to treat patients who progress



Ongoing questions / issues

- What is the best test?
 IHC, PCR, NGS (or combination)
- Identification of more people with Lynch syndrome
- Will benefit continue to endure after stopping pembrolizumab?
- GBM in patients after TMZ?
 - Safety in patients with CNS disease



TA beyond MSI-H/PD-1

- NTRK fusions?
 - Breakthrough designation publically announced for two drugs
 - Very rare in common tumors
 - Common in certain ultra-rare tumors
- TMB
 - How would indication (e.g., TMB cut-off) be defined?
 - Are IVD tests comparable?



Risks of TA Development / Trials

- Could slow drug development
 - By diverting resources from more common biomarkerpositive tumor types (e.g., via site selection)
 - Enrollment challenges for rare diseases
- Could increase development costs
 - e.g., increased sites, number of patients screened, etc.



How will TA approval impact development for biomarker negative populations?

- e.g., should MSI-H patients be excluded from clinical trials of single agent PD-1 inhibitors?
 - If not, how to assess whether an effect is driven solely by biomarker-positive population?



Acknowledgments

- Office of Hematology and Oncology Products
 - Richard Pazdur, M.D.
 - Amy McKee, M.D.
 - Gideon Blumenthal, M.D.
 - Patricia Keegan, M.D.
 - Leigh Marcus, M.D.
 - Damiette Smit, M.D.
 - Sharon Sickafuse
 - Monica Hughes, M.S.
 - Melanie Pierce

- Office of Biostatistics
 - Yuan, Weishi (Vivian)
 - Lisa Rodriguez



Thank you!

